Latest Technology News

MoneyMe Limited reported a robust FY25 with a $1.6 billion loan book, 28% growth from FY24, and a $24 million operating cash profit, signaling a strong turnaround. The fintech lender also improved credit quality and expanded funding capacity, setting the stage for future growth.

MONEYME Limited reported a robust FY25 with a 28% increase in its loan book to $1.6 billion and a positive operating cash profit of $24 million, underpinned by improved credit quality and strategic funding initiatives.

MoneyMe Limited posted a statutory net loss of $66.6 million for FY25, driven by accounting adjustments and credit loss provisions despite strong loan book growth and funding advances. The company is poised for growth with a new credit card launch and ongoing AI integration.

RAS Technology Holdings Limited reported a robust 31% revenue increase to $21.3 million in FY25, achieving its first after-tax profit following a strategic acquisition in Hong Kong that expanded its Asian footprint and recurring revenue.

Shine Justice Ltd reported a revenue increase to $204.4 million in FY25 despite a dip in adjusted net profit after tax, driven by strategic restructuring and a sharpened focus on personal injury and international mass torts. The company is investing in technology and expanding its US footprint to fuel growth in FY26.

dorsaVi appoints Mathew Regan as Group CEO to spearhead commercialisation of next-gen RRAM-enabled AI and robotics technologies, aiming for global expansion.

Cosmos Exploration’s optioned entity, EAU Lithium, has agreed to acquire a fully constructed pilot plant from Vulcan Energy Resources to advance lithium extraction testing in Bolivia. This move strengthens Cosmos’ strategic foothold in one of the world’s most promising lithium regions.

SomnoMed delivered a strong FY25 performance with revenue climbing 22% to $111.5 million and EBITDA turning positive at $9.2 million, boosted by operational improvements and FDA clearance of its Rest Assure device. The company projects further growth in FY26 with expanded manufacturing and ongoing innovation.

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

SomnoMed has delivered a standout FY25 with revenue and EBITDA exceeding market expectations, driven by strong regional growth and operational improvements. The company is now expanding capacity and advancing its innovative Rest Assure device.

SomnoMed Limited reported a record FY25 with $111.5 million revenue and a return to positive EBITDA, marking a milestone of over one million patients treated globally. The company secured FDA clearance for its Rest Assure® compliance tracking device and provided optimistic guidance for FY26.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.